Exploring New Biological Functions of Amyloids: Bacteria Cell Agglutination Mediated by Host Protein Aggregation

PLoS Pathogens

Volumn 8, Issue 11, 2012, Pages

  Torrent, Marc ^a,b   Pulido, David ^a   Nogués, M Victòria ^a   Boix, Ester ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; EOSINOPHIL CATIONIC PROTEIN; LIPOSOME;

ACINETOBACTER BAUMANNII; ANIMAL CELL; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL VIABILITY; BACTERIUM; CELL AGGLUTINATION; CELL DEATH; CELL SURFACE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ESCHERICHIA COLI; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE MICROSCOPY; IONIC STRENGTH; MINIMUM INHIBITORY CONCENTRATION; MODEL; NONHUMAN; PHOSPHOLIPID MEMBRANE; POINT MUTATION; PROTEIN AGGREGATION; PSEUDOMONAS AERUGINOSA; STRUCTURE ACTIVITY RELATION;

AMINO ACID SUBSTITUTION; AMYLOID; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; EOSINOPHIL CATIONIC PROTEIN; HUMANS; IMMUNITY, INNATE; MICROBIAL VIABILITY; MUTATION, MISSENSE;

BACTERIA (MICROORGANISMS);

EID: 84870827284     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003005     Document Type: Article

References (57)

1. Otvos L Jr, (2005) Antibacterial peptides and proteins with multiple cellular targets. J Pept Sci 11: 697-706.
2. Yount NY, Bayer AS, Xiong YQ, Yeaman MR, (2006) Advances in antimicrobial peptide immunobiology. Biopolymers 84: 435-458.
3. Zasloff M, (2002) Antimicrobial peptides of multicellular organisms. Nature 415: 389-395.
4. Hancock RE, Sahl HG, (2006) Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 24: 1551-1557.
5. Zhang L, Falla TJ, (2010) Potential therapeutic application of host defense peptides. Methods Mol Biol 618: 303-327.
6. Brogden KA, (2005) Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 3: 238-250.
7. Gottler LM, Ramamoorthy A, (2009) Structure, membrane orientation, mechanism, and function of pexiganan-a highly potent antimicrobial peptide designed from magainin. Biochim Biophys Acta 1788: 1680-1686.
8. Marsh EN, Buer BC, Ramamoorthy A, (2009) Fluorine-a new element in the design of membrane-active peptides. Mol Biosyst 5: 1143-1147.
9. Ramamoorthy A, (2009) Beyond NMR spectra of antimicrobial peptides: dynamical images at atomic resolution and functional insights. Solid State Nucl Magn Reson 35: 201-207.
10. Thennarasu S, Huang R, Lee DK, Yang P, Maloy L, et al. (2010) Limiting an antimicrobial peptide to the lipid-water interface enhances its bacterial membrane selectivity: a case study of MSI-367. Biochemistry 49: 10595-10605.
11. Pulido D, Nogues MV, Boix E, Torrent M, (2012) Lipopolysaccharide neutralization by antimicrobial peptides: a gambit in the innate host defense strategy. J Innate Immun 4: 327-336.
12. Torrent M, Nogues MV, Boix E, (2012) Discovering new in silico tools for antimicrobial Peptide prediction. Curr Drug Targets 13: 1148-1157.
13. Wimley WC, (2010) Describing the mechanism of antimicrobial peptide action with the interfacial activity model. ACS Chem Biol 5: 905-917.
14. Nguyen LT, Haney EF, Vogel HJ, (2011) The expanding scope of antimicrobial peptide structures and their modes of action. Trends Biotechnol 29: 464-472.
15. Butterfield SM, Lashuel HA, (2010) Amyloidogenic protein-membrane interactions: mechanistic insight from model systems. Angew Chem Int Ed Engl 49: 5628-5654.
16. Mahalka AK, Kinnunen PK, (2009) Binding of amphipathic alpha-helical antimicrobial peptides to lipid membranes: lessons from temporins B and L. Biochim Biophys Acta. 1788: 1600-1609.
17. Kagan BL, Jang H, Capone R, Teran Arce F, Ramachandran S, et al. (2011) Antimicrobial Properties of Amyloid Peptides. Mol Pharm 9: 708-717.
18. Brender JR, Durr UH, Heyl D, Budarapu MB, Ramamoorthy A, (2007) Membrane fragmentation by an amyloidogenic fragment of human Islet Amyloid Polypeptide detected by solid-state NMR spectroscopy of membrane nanotubes. Biochim Biophys Acta 1768: 2026-2029.
19. Brender JR, Hartman K, Gottler LM, Cavitt ME, Youngstrom DW, et al. (2009) Helical conformation of the SEVI precursor peptide PAP248-286, a dramatic enhancer of HIV infectivity, promotes lipid aggregation and fusion. Biophys J 97: 2474-2483.
20. Brender JR, Hartman K, Reid KR, Kennedy RT, Ramamoorthy A, (2008) A single mutation in the nonamyloidogenic region of islet amyloid polypeptide greatly reduces toxicity. Biochemistry 47: 12680-12688.
21. Brender JR, Lee EL, Cavitt MA, Gafni A, Steel DG, et al. (2008) Amyloid fiber formation and membrane disruption are separate processes localized in two distinct regions of IAPP, the type-2-diabetes-related peptide. J Am Chem Soc 130: 6424-6429.
22. Nanga RP, Brender JR, Vivekanandan S, Popovych N, Ramamoorthy A, (2009) NMR structure in a membrane environment reveals putative amyloidogenic regions of the SEVI precursor peptide PAP(248-286). J Am Chem Soc 131: 17972-17979.
23. Nanga RP, Brender JR, Xu J, Hartman K, Subramanian V, et al. (2009) Three-dimensional structure and orientation of rat islet amyloid polypeptide protein in a membrane environment by solution NMR spectroscopy. J Am Chem Soc 131: 8252-8261.
24. Popovych N, Brender JR, Soong R, Vivekanandan S, Hartman K, et al. (2012) Site specific interaction of the polyphenol EGCG with the SEVI amyloid precursor peptide PAP(248-286). J Phys Chem B 116: 3650-3658.
25. Jelinek R, Kolusheva S, (2005) Membrane interactions of host-defense peptides studied in model systems. Curr Protein Pept Sci 6: 103-114.
26. Tang M, Hong M, (2009) Structure and mechanism of beta-hairpin antimicrobial peptides in lipid bilayers from solid-state NMR spectroscopy. Mol Biosyst 5: 317-322.
27. Torrent M, Valle J, Nogues MV, Boix E, Andreu D, (2011) The generation of antimicrobial peptide activity: a trade-off between charge and aggregation? Angew Chem Int Ed Engl 50: 10686-10689.
28. Torrent M, Odorizzi F, Nogues MV, Boix E, (2010) Eosinophil cationic protein aggregation: identification of an N-terminus amyloid prone region. Biomacromolecules 11: 1983-1990.
29. Jang H, Arce FT, Mustata M, Ramachandran S, Capone R, et al. (2011) Antimicrobial protegrin-1 forms amyloid-like fibrils with rapid kinetics suggesting a functional link. Biophys J 100: 1775-1783.
30. Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, et al. (2010) The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One 5: e9505.
31. Harris F, Dennison SR, Phoenix DA, (2012) Aberrant action of amyloidogenic host defense peptides: a new paradigm to investigate neurodegenerative disorders? FASEB J 26: 1776-1781.
32. Torrent M, Andreu D, Nogues VM, Boix E, (2011) Connecting peptide physicochemical and antimicrobial properties by a rational prediction model. PLoS One 6: e16968.
33. Gorr SU, Sotsky JB, Shelar AP, Demuth DR, (2008) Design of bacteria-agglutinating peptides derived from parotid secretory protein, a member of the bactericidal/permeability increasing-like protein family. Peptides 29: 2118-2127.
34. Van Nieuw Amerongen A, Bolscher JG, Veerman EC, (2004) Salivary proteins: protective and diagnostic value in cariology? Caries Res 38: 247-253.
35. Pulido D, Moussaoui M, Andreu D, Nogues MV, Torrent M, et al. (2012) Antimicrobial Action and Cell Agglutination by Eosinophil Cationic Protein Is Modulated by the Cell Wall Lipopolysaccharide Structure. Antimicrob Agents Chemother 56: 2378-2385.
36. Boix E, Torrent M, Sánchez D, Nogués MV, (2008) The Antipathogen Activities of Eosinophil Cationic Protein. Current Pharm Biotec 9: 141-152.
37. Venge P, Bystrom J, Carlson M, Hakansson L, Karawacjzyk M, et al. (1999) Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin Exp Allergy 29: 1172-1186.
38. Boix E, Salazar VA, Torrent M, Pulido D, Nogues MV, et al. (2012) Structural determinants of the eosinophil cationic protein antimicrobial activity. Biol Chem 393: 801-815.
39. Torrent M, Badia M, Moussaoui M, Sanchez D, Nogues MV, et al. (2010) Comparison of human RNase 3 and RNase 7 bactericidal action at the Gram-negative and Gram-positive bacterial cell wall. FEBS J 277: 1713-1725.
40. Navarro S, Aleu J, Jimenez M, Boix E, Cuchillo CM, et al. (2008) The cytotoxicity of eosinophil cationic protein/ribonuclease 3 on eukaryotic cell lines takes place through its aggregation on the cell membrane. Cell Mol Life Sci 65: 324-337.
41. Torrent M, Navarro S, Moussaoui M, Nogues MV, Boix E, (2008) Eosinophil cationic protein high-affinity binding to bacteria-wall lipopolysaccharides and peptidoglycans. Biochemistry 47: 3544-3555.
42. Torrent M, Pulido D, de la Torre BG, Garcia-Mayoral MF, Nogues MV, et al. (2011) Refining the eosinophil cationic protein antibacterial pharmacophore by rational structure minimization. J Med Chem 54: 5237-5244.
43. Sanchez D, Moussaoui M, Carreras E, Torrent M, Nogues V, et al. (2011) Mapping the eosinophil cationic protein antimicrobial activity by chemical and enzymatic cleavage. Biochimie 93: 331-338.
44. Torrent M, Di Tommaso P, Pulido D, Nogues MV, Notredame C, et al. (2012) AMPA: an automated web server for prediction of protein antimicrobial regions. Bioinformatics 28: 130-131.
45. Torrent M, Nogues VM, Boix E, (2009) A theoretical approach to spot active regions in antimicrobial proteins. BMC Bioinformatics 10: 373.
46. Torrent M, de la Torre BG, Nogues VM, Andreu D, Boix E, (2009) Bactericidal and membrane disruption activities of the eosinophil cationic protein are largely retained in an N-terminal fragment. Biochem J 421: 425-434.
47. Torrent M, Nogues MV, Boix E, (2011) Eosinophil cationic protein (ECP) can bind heparin and other glycosaminoglycans through its RNase active site. J Mol Recognit 24: 90-100.
48. Kayed R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, et al. (2004) Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem 279: 46363-46366.
49. Ambroggio EE, Kim DH, Separovic F, Barrow CJ, Barnham KJ, et al. (2005) Surface behavior and lipid interaction of Alzheimer beta-amyloid peptide 1-42: a membrane-disrupting peptide. Biophys J 88: 2706-2713.
50. Auvynet C, El Amri C, Lacombe C, Bruston F, Bourdais J, et al. (2008) Structural requirements for antimicrobial versus chemoattractant activities for dermaseptin S9. FEBS J 275: 4134-4151.
51. Krstic D, Madhusudan A, Doehner J, Vogel P, Notter T, et al. (2012) Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. J Neuroinflammation 9: 151.
52. Miklossy J, (2011) Emerging roles of pathogens in Alzheimer disease. Expert Rev Mol Med 13: e30.
53. Almeida OP, Lautenschlager NT, (2005) Dementia associated with infectious diseases. Int Psychogeriatr 17 (Suppl 1):: S65-77.
54. Navarro S, Boix E, Cuchillo CM, Nogues MV, (2010) Eosinophil-induced neurotoxicity: the role of eosinophil cationic protein/RNase 3. J Neuroimmunol 227: 60-70.
55. Fredens K, Dahl R, Venge P, (1982) The Gordon phenomenon induced by the eosinophil cationic protein and eosinophil protein X. J Allergy Clin Immunol 70: 361-366.
56. Torrent M, Cuyas E, Carreras E, Navarro S, Lopez O, et al. (2007) Topography studies on the membrane interaction mechanism of the eosinophil cationic protein. Biochemistry 46: 720-733.
57. Torrent M, Sanchez D, Buzon V, Nogues MV, Cladera J, et al. (2009) Comparison of the membrane interaction mechanism of two antimicrobial RNases: RNase 3/ECP and RNase 7. Biochim Biophys Acta 1788: 1116-1125.